Abstract
Ninety-five patients with stage C (C1 + C2) or D (D1 + D2) prostatic carcinoma were treated with the depot formulation of D-TRP-6 LH-RH ('Decapeptyl') for up to 33 months. Serum testosterone (T) levels were significantly reduced to castration levels within 4 weeks and maintained persistently low. Similarly, LH levels were decreased, although they remained in the normal range. Stimulation tests with either Gn-RH or HCG in course of treatment showed the achievement of a complete pituitary desensitization and almost a complete down-regulation of testicular LH receptors. Of 88 patients evaluable for response about one-half showed an objective response. In most cases, subjective improvement with relief of bone pain and/or urinary symptoms was obtained without major side effects. These results indicate that the depot formulation of D-TRP-6 LH-RH offers an effective therapeutic alternative for patients with advanced prostatic cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 243-255 |
| Number of pages | 13 |
| Journal | Prostate |
| Volume | 11 |
| Issue number | 3 |
| Publication status | Published - 1987 |
Fingerprint
ASJC Scopus subject areas
- Urology
Cite this
Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer : An Italian prostatic cancer project (P.O.N.CA.P.) study. / Boccardo, F.; Decensi, A.; Guarneri, D.; Rubagotti, A.; Massa, T.; Martorana, G.; Giberti, C.; Cerruti, G. B.; Tani, F.; Zanollo, A.; Germinale, T.; Borzone, C.; Perri, F.; Usai, E.; Santi, L.; Giuliani, L.
In: Prostate, Vol. 11, No. 3, 1987, p. 243-255.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer
T2 - An Italian prostatic cancer project (P.O.N.CA.P.) study.
AU - Boccardo, F.
AU - Decensi, A.
AU - Guarneri, D.
AU - Rubagotti, A.
AU - Massa, T.
AU - Martorana, G.
AU - Giberti, C.
AU - Cerruti, G. B.
AU - Tani, F.
AU - Zanollo, A.
AU - Germinale, T.
AU - Borzone, C.
AU - Perri, F.
AU - Usai, E.
AU - Santi, L.
AU - Giuliani, L.
PY - 1987
Y1 - 1987
N2 - Ninety-five patients with stage C (C1 + C2) or D (D1 + D2) prostatic carcinoma were treated with the depot formulation of D-TRP-6 LH-RH ('Decapeptyl') for up to 33 months. Serum testosterone (T) levels were significantly reduced to castration levels within 4 weeks and maintained persistently low. Similarly, LH levels were decreased, although they remained in the normal range. Stimulation tests with either Gn-RH or HCG in course of treatment showed the achievement of a complete pituitary desensitization and almost a complete down-regulation of testicular LH receptors. Of 88 patients evaluable for response about one-half showed an objective response. In most cases, subjective improvement with relief of bone pain and/or urinary symptoms was obtained without major side effects. These results indicate that the depot formulation of D-TRP-6 LH-RH offers an effective therapeutic alternative for patients with advanced prostatic cancer.
AB - Ninety-five patients with stage C (C1 + C2) or D (D1 + D2) prostatic carcinoma were treated with the depot formulation of D-TRP-6 LH-RH ('Decapeptyl') for up to 33 months. Serum testosterone (T) levels were significantly reduced to castration levels within 4 weeks and maintained persistently low. Similarly, LH levels were decreased, although they remained in the normal range. Stimulation tests with either Gn-RH or HCG in course of treatment showed the achievement of a complete pituitary desensitization and almost a complete down-regulation of testicular LH receptors. Of 88 patients evaluable for response about one-half showed an objective response. In most cases, subjective improvement with relief of bone pain and/or urinary symptoms was obtained without major side effects. These results indicate that the depot formulation of D-TRP-6 LH-RH offers an effective therapeutic alternative for patients with advanced prostatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=0023499491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023499491&partnerID=8YFLogxK
M3 - Article
C2 - 2960957
AN - SCOPUS:0023499491
VL - 11
SP - 243
EP - 255
JO - Prostate
JF - Prostate
SN - 0270-4137
IS - 3
ER -